Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
| Revenue (Most Recent Fiscal Year) | $0.30M |
| Net Income (Most Recent Fiscal Year) | $-269.95M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4990.75 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -112806.88% |
| Net Margin (Trailing 12 Months) | -112806.88% |
| Return on Equity (Trailing 12 Months) | -78.95% |
| Return on Assets (Trailing 12 Months) | -49.91% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.83 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 81.66M |
| Free Float | 80.37M |
| Market Capitalization | $1.52B |
| Average Volume (Last 20 Days) | 0.85M |
| Beta (Past 60 Months) | 0.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.58% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |